News

September 7, 2021
IGM Biosciences to Participate in Three Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in three upcoming investor conferences: Citi 16 th
Additional Formats
June 3, 2021
IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Nature Demonstrating Engineered IgM Antibody Antiviral Activity for the Treatment and Prevention of COVID-19
Company Expects to Advance First Intranasally Administered IgM Antibody, IGM-6268, into the Clinic in Third Quarter of 2021 MOUNTAIN VIEW, Calif. , June 03, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS) a clinical-stage biotechnology company focused on creating and developing
Additional Formats
April 27, 2021
IGM Biosciences to Present at the Truist Securities Life Sciences Summit
MOUNTAIN VIEW, Calif. , April 27, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will participate in a fireside chat at
Additional Formats
April 12, 2021
IGM Biosciences Appoints George Gauthier as Chief Commercial Officer
Mr. Gauthier Brings 20 Years of Global Commercial Experience in the Life Sciences Industry MOUNTAIN VIEW, Calif. , April 12, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today
Additional Formats
Displaying 1 - 10 of 16